BOSTON, Mass. (WLNE) – Blue Cross Blue Shield of Massachusetts will not be covering Aduhelm, a controversial new Alzheimer's drug. Blue Cross says while the drug shows promise, studies do not demonstrate that the benefits outweigh the risks.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
